WO2012064306A2 - Effervescent formulations of rosuvastatin - Google Patents

Effervescent formulations of rosuvastatin Download PDF

Info

Publication number
WO2012064306A2
WO2012064306A2 PCT/TR2011/000248 TR2011000248W WO2012064306A2 WO 2012064306 A2 WO2012064306 A2 WO 2012064306A2 TR 2011000248 W TR2011000248 W TR 2011000248W WO 2012064306 A2 WO2012064306 A2 WO 2012064306A2
Authority
WO
WIPO (PCT)
Prior art keywords
effervescent
formulations
mixture
acid
formulation according
Prior art date
Application number
PCT/TR2011/000248
Other languages
French (fr)
Other versions
WO2012064306A3 (en
Inventor
Bilgic Mahmut
Original Assignee
Bilgic Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bilgic Mahmut filed Critical Bilgic Mahmut
Publication of WO2012064306A2 publication Critical patent/WO2012064306A2/en
Publication of WO2012064306A3 publication Critical patent/WO2012064306A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to effervescent formulations comprising rosuvastatin and/or a pharmaceutically acceptable salt thereof as active agent.
  • the Prior Art Rosuvastatin which was first disclosed in the patent numbered US5260440 (A), is an HMG Co A enzyme inhibitor having the chemical name (3i?,5S,6E)-7-[4-(4-fluorophenyl)-6-(l- methylethyl)-2[methyl(methylsulphonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid illustrated in formula (I):
  • rosuvastatin which is displayed in formula (I) in the patent numbered US 5260440, prevents cholesterol formation by inhibiting the activation of the enzyme named HMG-CoA reductase that is responsible for cholesterol synthesis in the body and it is effective in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis.
  • Rosuvastatin formulations in the prior art are in tablet form.
  • Rosuvastatin formulations marketed under the trade name "Crestor®” are in tablet forms of 5, 10, 20 and 40 mg comprising rosuvastatin calcium.
  • these formulations hold some disadvantages that tablet dosage form brings along.
  • tablet dosage form has low bioavailability compared with suspension dosage forms.
  • highest bioavailability is obtained from oral solutions.
  • dosage forms such as tablet and capsule pose swallowing difficulty for particularly elderly and physically handicapped patients as they are hard to swallow even when taken with liquid and have unpleasant taste. In parallel with this, these patients do not take their medication regularly and this substantially affects the efficiency of the treatment.
  • Suspension dosage forms are not preferred because of their short shelf life.
  • Effervescent dosage forms developed as an alternative to the dosage forms listed above are more advantageous compared with the conventional forms due to fast dissolving.
  • Effervescent formulations are dissolved fast, release the active agent/agents into the aqueous liquid simultaneously and fast.
  • the time spent between addition of the formulation into water or its dissolution or intake of the solution is relatively short. Consumption of the formulations in a short time impedes the degradation of the active agent with water; therefore, this type of formulations consumed in a short time do not require high amounts of stabilizing agent.
  • formulations in effervescent form are particularly preferred by patients in terms of ease of use and carrying. This type of formulations are more advantageous for use of elderly and physically handicapped patients. Formulation is rapidly dispersed in aqueous liquid and can be administered by the oral route, with a spoon or as a drop when necessary.
  • effervescent dosage forms comprising rosuvastatin and/or pharmaceutically acceptable salts thereof is their insufficient dissolution and failure to create a clear solution when mixed with water.
  • effervescent dosage forms comprising rosuvastatin and/or pharmaceutically acceptable salts thereof and the problems they hold have not been referred to.
  • the inventors have found that sufficient dissolution is surprisingly ensured and a clear solution is obtained when an organic salt with divalent cation is used.
  • the first embodiment of the invention relates to advanced pharmaceutical formulations comprising rosuvastatin in therapeutically effective amounts.
  • a characteristic feature of the formulations of the present invention is that said formulations are in effervescent form.
  • formulations comprise a pharmaceutically acceptable organic salt with divalent cation in order to provide sufficient dissolution.
  • organic salt is selected from a group comprising calcium bicarbonate and magnesium carbonate.
  • the organic salt with divalent cation used in the formulations of the present invention is preferably calcium carbonate.
  • amount of the organic salt which is used in order to ensure sufficient dissolution and have divalent cation is in the range of 1% to 10%, preferably in the range of 1% to 5% by weight.
  • effervescent formulations comprise at least one effervescent acid, at least one effervescent base and at least one other pharmaceutically acceptable excipient in addition to these.
  • the effervescent base is selected from a group excluding calcium carbonate.
  • formulations of the present invention comprises at least two effervescent acids which are chemically different.
  • Effervescent formulations produced according to the present invention can easily form clear solutions in water and do not require use of high amounts of stabilizing agent. These formulations are dissolved in a particular amount of water and/or a similar liquid regardless of temperature of the liquid.
  • Effervescent formulations can be produced in water soluble tablet, granule or powder form.
  • Effervescent formulations of the present invention can comprise at least one antihypertensive substance in an effective amount, preferably one or more sterol absorption inhibitor as a second active agent.
  • the sterol absorption inhibitor used in rosuvastatin formulations of the present invention is preferably ezetimibe and/or its pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms and/or combinations thereof.
  • pharmaceutically acceptable derivatives used throughout the text refers to salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of the active agent and/or combinations thereof.
  • Effervescent pharmaceutical formulations of the present invention comprise other pharmaceutically acceptable components such as additives and excipients selected from disintegrants, viscosity enhancing agents, filling agents, drying agents, stabilizing agents, lubricants, diluents, binders, glidants, anti-foam agents, wetting agents, effervescent mixtures, sweeteners and flavoring agents.
  • additives and excipients selected from disintegrants, viscosity enhancing agents, filling agents, drying agents, stabilizing agents, lubricants, diluents, binders, glidants, anti-foam agents, wetting agents, effervescent mixtures, sweeteners and flavoring agents.
  • the effervescent mixtures comprised in the effervescent formulations of the present invention are composed of at least one pharmaceutically acceptable effervescent base and at least one effervescent acid.
  • the effervescent bases to be used in the effervescent formulations of the present invention can be selected from a group comprising sodium, potassium and calcium carbonates, bicarbonates and/or sodium glycine carbonate or a combination thereof.
  • the effervescent base used in the effervescent formulations of the present invention is selected from a group excluding calcium carbonate though it is preferably sodium hydrogen carbonate.
  • the effervescent acids to be used in the effervescent formulations of the present invention can be a pharmaceutically acceptable anhydrous organic or inorganic acid, especially citric acid, monosodium citrate, tartaric acid, fumaric acid, malic acid and/or their pharmaceutically acceptable salts, hydrates, anhydrates or preferably a combination thereof.
  • Effervescent formulations of the present invention comprise at least two effervescent acids selected from the group listed above.
  • the effervescent acid comprised in the effervescent formulations of the present invention is a mixture of at least two effervescent acids which are chemically different.
  • the diluents that can be used in the effervescent formulations of the present invention comprises one or more components selected from the group comprising alkaline metal carbonates, cellulose derivatives (microcrystalline cellulose, cellulose acetate etc.), dextrin, fructose, dextrose, glyceryl palmito stearate, lactitol, lactose, directly compressible lactose, maltose, mannitol, simethicone, sorbitol, starch, talc, xylitol and/or hydrates thereof and/or derivatives thereof.
  • antioxidants In the effervescent formulations of the present invention, antioxidants, chelating agents, alkalinizing agents and photoprotective agents can be used as stabilizing agent.
  • the stabilizing agents that can be used in the effervescent formulations of the present invention can be selected from alkaline metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline-earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; organic components such as primary, secondary and tertiary amines, cyclic amines, N,N'-dibenzyl ethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium, sodium alginate and/or pharmaceutically acceptable hydrates and/or derivatives thereof.
  • the disintegrants that can be used in the effervescent formulations of the present invention can be selected from highly dispersive polymers, for instance cross-linked hydroxypropyl cellulose, polyvinylpyrrolidone, high-molecular-weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, alginic acid, sodium alginate.
  • highly dispersive polymers for instance cross-linked hydroxypropyl cellulose, polyvinylpyrrolidone, high-molecular-weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, alginic acid, sodium alginate.
  • the binders that can be used in the effervescent formulations of the present invention comprise one or more components selected from the group comprising potato, wheat or corn starch; microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hypromellose and polyvinylpyrrolidone.
  • the filling agents that can be used in the effervescent formulations of the present invention comprises one or more components selected from the group comprising lactose, sugar, starch, modified starch, mannitol, sorbitol, inorganic salts, microcrystalline cellulose, cellulose, calcium sulphate, xylitol and lactitol.
  • the lubricants that can be used in the effervescent formulations of the present invention comprise one or more components selected from the group comprising highly metallic stearates (magnesium stearate, calcium stearate, aluminium stearate etc), fatty acid esters (sodium stearyl fumarate etc), fatty acids (stearic acid etc), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate and talc and/or hydrates thereof.
  • highly metallic stearates magnesium stearate, calcium stearate, aluminium stearate etc
  • fatty acid esters sodium stearyl fumarate etc
  • fatty acids stearic acid etc
  • fatty alcohols glyceryl behenate,
  • the effervescent formulations of the present invention can comprise at least one taste regulating agent in addition to one or more sweeteners.
  • the effervescent formulations of the present invention comprise;
  • Rosuvastatin calcium in the range of 0.1 % to 5%
  • Effervescent formulations of the present invention can be produced using the techniques in the prior art such as wet or dry granulation techniques.
  • formulations of the present invention are used in prophylaxis and/or treatment of atherosclerosis, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, myocardial infarction, stroke.
  • Example 1 Effervescent formulation comprising rosuvastatin calcium
  • rosuvastatin calcium, calcium carbonate and at least one other pharmaceutically acceptable excipient are mixed.
  • the active agent mixture obtained is preferably granulated wet with deionized water.
  • the rosuvastatin granules obtained are dried and sieved.

Abstract

The present invention relates to effervescent formulations comprising rosuvastatin and/or a pharmaceutically acceptable salt thereof as active agent.

Description

EFFERVESCENT FORMULATIONS OF ROSUVASTATIN
The present invention relates to effervescent formulations comprising rosuvastatin and/or a pharmaceutically acceptable salt thereof as active agent.
The Prior Art Rosuvastatin, which was first disclosed in the patent numbered US5260440 (A), is an HMG Co A enzyme inhibitor having the chemical name (3i?,5S,6E)-7-[4-(4-fluorophenyl)-6-(l- methylethyl)-2[methyl(methylsulphonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic acid illustrated in formula (I):
Figure imgf000002_0001
(I)
It is indicated that rosuvastatin, which is displayed in formula (I) in the patent numbered US 5260440, prevents cholesterol formation by inhibiting the activation of the enzyme named HMG-CoA reductase that is responsible for cholesterol synthesis in the body and it is effective in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis. Rosuvastatin formulations in the prior art are in tablet form. Rosuvastatin formulations marketed under the trade name "Crestor®" are in tablet forms of 5, 10, 20 and 40 mg comprising rosuvastatin calcium. However, these formulations hold some disadvantages that tablet dosage form brings along.
The first and the most significant disadvantage of tablet dosage form is its low bioavailability compared with suspension dosage forms. As it is known, highest bioavailability is obtained from oral solutions. At the same time, dosage forms such as tablet and capsule pose swallowing difficulty for particularly elderly and physically handicapped patients as they are hard to swallow even when taken with liquid and have unpleasant taste. In parallel with this, these patients do not take their medication regularly and this substantially affects the efficiency of the treatment. Suspension dosage forms, on the other hand, are not preferred because of their short shelf life.
Effervescent dosage forms developed as an alternative to the dosage forms listed above are more advantageous compared with the conventional forms due to fast dissolving. Effervescent formulations are dissolved fast, release the active agent/agents into the aqueous liquid simultaneously and fast. The time spent between addition of the formulation into water or its dissolution or intake of the solution is relatively short. Consumption of the formulations in a short time impedes the degradation of the active agent with water; therefore, this type of formulations consumed in a short time do not require high amounts of stabilizing agent.
In addition, pharmaceutical formulations in effervescent form are particularly preferred by patients in terms of ease of use and carrying. This type of formulations are more advantageous for use of elderly and physically handicapped patients. Formulation is rapidly dispersed in aqueous liquid and can be administered by the oral route, with a spoon or as a drop when necessary.
However, the problem about effervescent dosage forms comprising rosuvastatin and/or pharmaceutically acceptable salts thereof is their insufficient dissolution and failure to create a clear solution when mixed with water.
Insufficient dissolution impedes administration of required amount of the active agent to the patient and thus lead to decrease in efficiency of the treatment.
At the same time, patients do not want to drink the solution blurred due to the particles suspended in water. To this respect, the active agent rosuvastatin has not been formulated in effervescent form so far.
In the prior art, effervescent dosage forms comprising rosuvastatin and/or pharmaceutically acceptable salts thereof and the problems they hold have not been referred to. As a result of research and development studies they conducted on effervescent rosuvastatin formulations, the inventors have found that sufficient dissolution is surprisingly ensured and a clear solution is obtained when an organic salt with divalent cation is used.
Detailed Description of The Invention The first embodiment of the invention relates to advanced pharmaceutical formulations comprising rosuvastatin in therapeutically effective amounts.
A characteristic feature of the formulations of the present invention is that said formulations are in effervescent form.
Another characteristic feature of the present invention is that said formulations comprise a pharmaceutically acceptable organic salt with divalent cation in order to provide sufficient dissolution.
Another characteristic feature of the present invention is that said organic salt is selected from a group comprising calcium bicarbonate and magnesium carbonate.
The organic salt with divalent cation used in the formulations of the present invention is preferably calcium carbonate.
Another characteristic feature of the formulations of the present invention is that amount of the organic salt which is used in order to ensure sufficient dissolution and have divalent cation is in the range of 1% to 10%, preferably in the range of 1% to 5% by weight.
Another characteristic feature of the formulations of the present invention is that effervescent formulations comprise at least one effervescent acid, at least one effervescent base and at least one other pharmaceutically acceptable excipient in addition to these.
Another characteristic feature of the formulations of the present invention is that the effervescent base is selected from a group excluding calcium carbonate.
Another characteristic feature of the formulations of the present invention is that said formulation comprises at least two effervescent acids which are chemically different.
Effervescent formulations produced according to the present invention can easily form clear solutions in water and do not require use of high amounts of stabilizing agent. These formulations are dissolved in a particular amount of water and/or a similar liquid regardless of temperature of the liquid.
Effervescent formulations can be produced in water soluble tablet, granule or powder form.
Effervescent formulations of the present invention can comprise at least one antihypertensive substance in an effective amount, preferably one or more sterol absorption inhibitor as a second active agent. The sterol absorption inhibitor used in rosuvastatin formulations of the present invention is preferably ezetimibe and/or its pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms and/or combinations thereof. The term "pharmaceutically acceptable derivatives" used throughout the text refers to salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms of the active agent and/or combinations thereof.
Effervescent pharmaceutical formulations of the present invention comprise other pharmaceutically acceptable components such as additives and excipients selected from disintegrants, viscosity enhancing agents, filling agents, drying agents, stabilizing agents, lubricants, diluents, binders, glidants, anti-foam agents, wetting agents, effervescent mixtures, sweeteners and flavoring agents.
The effervescent mixtures comprised in the effervescent formulations of the present invention are composed of at least one pharmaceutically acceptable effervescent base and at least one effervescent acid.
The effervescent bases to be used in the effervescent formulations of the present invention can be selected from a group comprising sodium, potassium and calcium carbonates, bicarbonates and/or sodium glycine carbonate or a combination thereof.
The effervescent base used in the effervescent formulations of the present invention is selected from a group excluding calcium carbonate though it is preferably sodium hydrogen carbonate.
The effervescent acids to be used in the effervescent formulations of the present invention can be a pharmaceutically acceptable anhydrous organic or inorganic acid, especially citric acid, monosodium citrate, tartaric acid, fumaric acid, malic acid and/or their pharmaceutically acceptable salts, hydrates, anhydrates or preferably a combination thereof. Effervescent formulations of the present invention comprise at least two effervescent acids selected from the group listed above.
In other terms, the effervescent acid comprised in the effervescent formulations of the present invention is a mixture of at least two effervescent acids which are chemically different. The diluents that can be used in the effervescent formulations of the present invention comprises one or more components selected from the group comprising alkaline metal carbonates, cellulose derivatives (microcrystalline cellulose, cellulose acetate etc.), dextrin, fructose, dextrose, glyceryl palmito stearate, lactitol, lactose, directly compressible lactose, maltose, mannitol, simethicone, sorbitol, starch, talc, xylitol and/or hydrates thereof and/or derivatives thereof.
In the effervescent formulations of the present invention; antioxidants, chelating agents, alkalinizing agents and photoprotective agents can be used as stabilizing agent.
The stabilizing agents that can be used in the effervescent formulations of the present invention can be selected from alkaline metal salts such as sodium carbonate, sodium hydrogen carbonate, sodium hydroxide, sodium silicate, disodium hydrogen orthophosphate, sodium aluminate; alkaline-earth metal salts such as calcium carbonate, calcium hydroxide, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulphate, calcium acetate, calcium gluconate, calcium glycerophosphate, magnesium carbonate, magnesium hydroxide, magnesium sulphate, magnesium acetate, magnesium silicate, magnesium aluminate; organic components such as primary, secondary and tertiary amines, cyclic amines, N,N'-dibenzyl ethylenediamine, diethanolamine, ethylenediamine, meglumine, monosodium glutamate, polacrilin sodium, sodium alginate and/or pharmaceutically acceptable hydrates and/or derivatives thereof.
The disintegrants that can be used in the effervescent formulations of the present invention can be selected from highly dispersive polymers, for instance cross-linked hydroxypropyl cellulose, polyvinylpyrrolidone, high-molecular-weight polymers, microcrystalline cellulose, sodium starch glycolate, povidone, alginic acid, sodium alginate.
The binders that can be used in the effervescent formulations of the present invention comprise one or more components selected from the group comprising potato, wheat or corn starch; microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hypromellose and polyvinylpyrrolidone. The filling agents that can be used in the effervescent formulations of the present invention comprises one or more components selected from the group comprising lactose, sugar, starch, modified starch, mannitol, sorbitol, inorganic salts, microcrystalline cellulose, cellulose, calcium sulphate, xylitol and lactitol.
The lubricants that can be used in the effervescent formulations of the present invention comprise one or more components selected from the group comprising highly metallic stearates (magnesium stearate, calcium stearate, aluminium stearate etc), fatty acid esters (sodium stearyl fumarate etc), fatty acids (stearic acid etc), fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), metallic lauryl sulphates (sodium lauryl sulphate, magnesium lauryl sulphate), sodium chloride, sodium benzoate, sodium acetate and talc and/or hydrates thereof.
The sweeteners that can be used in the effervescent formulations of the present invention comprise one or more components selected from the group comprising aspartame, dextrose, fructose, sucralose, sodium cyclamate, mannitol, maltose, saccharine and/or pharmaceutically acceptable salts thereof.
The effervescent formulations of the present invention can comprise at least one taste regulating agent in addition to one or more sweeteners.
The flavouring agents that can be used in the effervescent formulations of the present invention can be banana, strawberry, lemon, orange, peach, vanilla or similar natural fruit or aromatic plant flavours.
The effervescent formulations of the present invention comprise;
• Rosuvastatin calcium in the range of 0.1 % to 5%
• An organic salt with divalent cation in the range of 1 % to 10%
• At least two different effervescent acid in the range of 40% to 70%
· At least one effervescent base in the range of 10% to 40%
• One or more pharmaceutical excipient in the range of 1% to 20%
Effervescent formulations of the present invention can be produced using the techniques in the prior art such as wet or dry granulation techniques.
Another characteristic feature of the formulations of the present invention is that said formulations are used in prophylaxis and/or treatment of atherosclerosis, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, myocardial infarction, stroke.
The examples below are given so as to clarify the invention. These examples does not limit the scope of the invention and are considered with the explanation part given in detail above.
Example 1. Effervescent formulation comprising rosuvastatin calcium
Figure imgf000008_0001
The method for the effervescent tablet of rosuvastatin to be produced according to the formulation given above is as follows:
1. An effective amount of rosuvastatin calcium, calcium carbonate and at least one other pharmaceutically acceptable excipient are mixed.
2. The active agent mixture obtained is preferably granulated wet with deionized water.
3. The rosuvastatin granules obtained are dried and sieved.
4. Other pharmaceutically acceptable excipients are added into the dry mixture and the end mixture is sent to tablet compression machine.

Claims

1. An effervescent formulation comprising rosuvastatin and/or a pharmaceutically acceptable salt thereof as active agent characterized in that said formulations comprise at least one organic salt in which the cation is divalent.
2. The effervescent formulation according to claim 1 characterized in that the organic salt with divalent cation is calcium carbonate or magnesium carbonate.
3. The effervescent formulation according to claim 2 characterized in that the organic salt comprised in said formulations is calcium carbonate.
4. The effervescent formulation according to any preceding claims characterized in that the amount of the organic salt used in the formulations is in the range of 1% to 10% by weight.
5. The effervescent formulation according to claim 4 characterized in that the amount of the organic salt used in the formulations is in the range of 1% to 5% by weight.
6. The effervescent formulation according to any preceding claims characterized in that rosuvastatin used in the formulations is in calcium salt form.
7. The effervescent formulation according to claim 6 characterized in that the amount of rosuvastatin calcium used in the formulations is in the range of 0.1% to 5% by weight.
8. The effervescent formulation according to claim 7 characterized in that the amount of rosuvastatin calcium used in the formulations is in the range of 0.1% to 2% by weight.
9. The effervescent formulation according to claim 1 characterized in that said formulation comprises other pharmaceutically acceptable components such as additives and excipients selected from disintegrants, viscosity enhancing agents, filling agents, drying agents, stabilizing agents, lubricants, diluents, binders, glidants, anti-foam agents, wetting agents, effervescent mixtures, sweeteners and flavoring agents.
10. The effervescent formulation according to claim 9 characterized in that the effervescent mixture in the formulations is composed of at least one effervescent acid and at least one effervescent base.
11. The effervescent mixture according to claim 10 characterized in that the effervescent base in the mixture is selected from a group excluding calcium carbonate.
12. The effervescent mixture according to claim 11 characterized in that the effervescent base in the mixture is selected from a group comprising sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate.
13. The effervescent base according to claim 12, wherein said effervescent base is preferably sodium hydrogen carbonate.
14. The effervescent mixture according to claim 10 characterized in that the effervescent acid in the mixture is a mixture of at least two effervescent acids which are chemically different.
15. The effervescent mixture according to claim 14 characterized in that the effervescent acid in the mixture is selected from a group comprising citric acid, monosodium citrate, tartaric acid, fumaric acid, malic acid and/or their pharmaceutically acceptable salts, hydrates, anhydrates or preferably a combination thereof.
16. The effervescent mixture according to claim 15 characterized in that the effervescent acid in the mixture preferably comprises malic acid and citric acid anhydrate.
17. The effervescent formulation according to claim 9 characterized in that the lubricant in said formulations is selected from a group comprising magnesium stearate, calcium stearate, aluminium stearate, sodium stearyl fumarate, stearic acid, fatty alcohols, glyceryl behenate, mineral oil, paraffins, hydrogenated vegetable oils, leucine, polyethylene glycols (PEG), sodium lauryl sulphate, magnesium lauryl sulphate, sodium chloride, sodium benzoate, sodium acetate and talc and/or hydrates thereof.
18. The effervescent formulation according to claim 1 characterized in that said formulation comprises at least one sterol absorption inhibitor as a second active agent.
19. The sterol absorption inhibitor according to claim 18, wherein said sterol absorption inhibitor is preferably ezetimibe and/or its pharmaceutically acceptable salts, hydrates, enantiomers, racemates, organic salts, inorganic salts, esters, polymorphs, crystalline forms and amorphous forms and/or combinations thereof.
20. The effervescent formulation according to any preceding claims characterized in that said formulation is used in prophylaxis and/or treatment of atherosclerosis, hypercholesterolemia, hyperlipoproteinemia, hypertriglyceridemia, myocardial infarction, stroke.
PCT/TR2011/000248 2010-11-11 2011-11-03 Effervescent formulations of rosuvastatin WO2012064306A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/09399 2010-11-11
TR2010/09399A TR201009399A2 (en) 2010-11-11 2010-11-11 Rapidly soluble effervescent rosuvastatin formulations.

Publications (2)

Publication Number Publication Date
WO2012064306A2 true WO2012064306A2 (en) 2012-05-18
WO2012064306A3 WO2012064306A3 (en) 2012-08-09

Family

ID=45607337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000248 WO2012064306A2 (en) 2010-11-11 2011-11-03 Effervescent formulations of rosuvastatin

Country Status (2)

Country Link
TR (1) TR201009399A2 (en)
WO (1) WO2012064306A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
US11576855B2 (en) 2014-09-17 2023-02-14 Steerlife India Private Limited Effervescent composition and method of making it

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260440A (en) 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872544A1 (en) * 1997-04-14 1998-10-21 The Procter & Gamble Company Dry effervescent granules and granular compositions comprising the same
US20070048375A1 (en) * 2003-12-19 2007-03-01 Wolfgang Wiehl Effervescent preparation of a basic medicinally active substance
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
US20090304602A1 (en) * 2008-06-06 2009-12-10 Tuchinsky David B Nutritional supplement
PL386051A1 (en) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stable, oral compound pharmaceutical containing pharmaceutically permissible content of [(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3R,5S)-3,5-dihydroxy-hept-6-enoate acid salt
CN101618215A (en) * 2009-08-16 2010-01-06 王丽燕 Pharmaceutical composition containing calcium blocker, AII receptor blocker and statins
TR201009397A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions containing rosuvastatin.
EP2575757A1 (en) * 2010-06-03 2013-04-10 Mahmut Bilgic Water soluble formulation comprising a combination of amlodipine and a statin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260440A (en) 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11576855B2 (en) 2014-09-17 2023-02-14 Steerlife India Private Limited Effervescent composition and method of making it
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof

Also Published As

Publication number Publication date
TR201009399A2 (en) 2012-05-21
WO2012064306A3 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
JP4219399B2 (en) Dispersible tablets
ES2755273T3 (en) Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate control composition
CA2588465C (en) Pharmaceutical composition containing an anti-nucleating agent
WO2012064307A1 (en) Pharmaceutical compositions comprising rosuvastatin
CZ290167B6 (en) Pharmaceutical composition and use of a tribasic phosphate salt
JP7094944B2 (en) Pharmaceutical composition containing rosuvastatin and ezetimibe and method for preparing the same
US20090136570A1 (en) Taste-Masked Tablets and Granules
WO2023078604A1 (en) Formulations of psilocybin analogs and methods of use
EP2575757A1 (en) Water soluble formulation comprising a combination of amlodipine and a statin
WO2012002547A1 (en) Bosentan solid dispersion
WO2012064306A2 (en) Effervescent formulations of rosuvastatin
EP2566448A2 (en) Efervescent formulations comprising cefdinir
WO2011093828A2 (en) Solid dosage forms comprising cefprozil
WO2012060786A2 (en) Cefpodoxime proxetil formulations comprising viscosity agent
WO2011139253A2 (en) Pharmaceutical compositions comprising ceftibuten
WO2011129792A1 (en) Water dispersible formulations comprising cefpodoxime proxetil
WO2019116386A1 (en) Oral pharmaceutical compositions of amorphous apremilast and process for preparing thereof
WO2010140992A1 (en) Stable pharmaceutical compositions containing rosuvastatin calcium
WO2011139255A2 (en) Pharmaceutical compositions comprising cefetamet
JP5956034B1 (en) Telmisartan-containing pharmaceutical composition
EP4034127A1 (en) Effervescent formulations of sapropterin dihydrochloride
WO2013109224A1 (en) Pharmaceutical compositions comprising diclofenac
EP2663289A2 (en) Cefpodoxime proxetil formulations comprising taste regulating agent
KR20090033246A (en) Oral pharmaceutical composition of a poorly water-soluble active substance
TW200808356A (en) Improved oral pharmaceutical composition of a poorly water-soluble active substance

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817550

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011817550

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 11817550

Country of ref document: EP

Kind code of ref document: A2